Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 139 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2015', provides an overview of the Systemic Sclerosis (Scleroderma)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Systemic Sclerosis (Scleroderma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Systemic Sclerosis (Scleroderma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Systemic Sclerosis (Scleroderma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Systemic Sclerosis (Scleroderma) Overview 10
Therapeutics Development 11
Pipeline Products for Systemic Sclerosis (Scleroderma) - Overview 11
Pipeline Products for Systemic Sclerosis (Scleroderma) - Comparative Analysis 12
Systemic Sclerosis (Scleroderma) - Therapeutics under Development by Companies 13
Systemic Sclerosis (Scleroderma) - Therapeutics under Investigation by Universities/Institutes 16
Systemic Sclerosis (Scleroderma) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Systemic Sclerosis (Scleroderma) - Products under Development by Companies 20
Systemic Sclerosis (Scleroderma) - Products under Investigation by Universities/Institutes 22
Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 23
Active Biotech AB 23
Allergan, Inc. 24
Angion Biomedica Corp. 25
arGentis Pharmaceuticals, LLC 26
Auspex Pharmaceuticals, Inc. 27
Bayer AG 28
BioLineRx, Ltd. 29
Bristol-Myers Squibb Company 30
Celgene Corporation 31
Corbus pharmaceuticals, Inc. 32
Daval International Ltd. 33
Digna Biotech, S.L. 34
Dynavax Technologies Corporation 35
F. Hoffmann-La Roche Ltd. 36
Fibrocell Science, Inc. 37
GlaxoSmithKline plc 38
iBio, Inc. 39
Inventiva SAS 40
MedImmune, LLC 41
NovaLead Pharma Pvt. Ltd. 42
Vida Therapeutics Inc. 43
VivaCell Biotechnology Espana S.L. 44
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
abatacept (recombinant) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
acALY-18 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Aimspro - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ANG-3070 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ARG-201 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
belimumab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BL-1110 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CC-220 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
disitertide - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
DV-1179 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GMHDFCOL-7 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
IBIOCFB-03 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
IVA-337 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
JBT-101 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MEDI-551 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NLP-491 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Oligonucleotide for Scleroderma - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
onabotulinumtoxin A - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
P-17 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
paquinimod - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
PAT-048 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
pomalidomide - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
riociguat - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SD-560 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule to Inhibit NFkB for Immunology and Oncology - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Stem Cell Therapy for Crohns Disease and Systemic Sclerosis - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
tocilizumab - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
V-2248 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
VCE-0048 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
VEDA-1209 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Systemic Sclerosis (Scleroderma) - Recent Pipeline Updates 102
Systemic Sclerosis (Scleroderma) - Dormant Projects 129
Systemic Sclerosis (Scleroderma) - Discontinued Products 131
Systemic Sclerosis (Scleroderma) - Product Development Milestones 132
Featured News & Press Releases 132
Jan 07, 2015: Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences 132
Dec 10, 2014: iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting 132
Dec 08, 2014: Cureveda Awarded Two NIH Small Business Grants to Develop Treatments for Systemic Sclerosis and COPD 134
Dec 03, 2014: Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014 134
Nov 03, 2014: Inventiva receives positive opinion on orphan drug designation in the European Union for IVA337 - a treatment for Systemic Sclerosis (SSc) 135
Oct 22, 2014: iBio Expands Exclusive Product Collaboration With Novici Biotech 135
Oct 01, 2014: Corbus Pharmaceuticals to Present at the 13th Annual BIO Investor Forum in San Francisco on Wednesday, October 8, 2014 136
Sep 30, 2014: Corbus Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable in New York on Wednesday, October 1, 2014 136
Jun 11, 2014: Active Biotech Presents Data On Paquinimod At Eular 2014 136
Feb 25, 2014: Daval International Announces the Granting of Orphan Drug Designation by the FDA for AIMSPRO 137
Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 138
Disclaimer 139

List of Tables
Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2015 11
Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Development, H1 2015 19
Products under Development by Companies, H1 2015 20
Products under Development by Companies, H1 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Systemic Sclerosis (Scleroderma) - Pipeline by Active Biotech AB, H1 2015 23
Systemic Sclerosis (Scleroderma) - Pipeline by Allergan, Inc., H1 2015 24
Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp., H1 2015 25
Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals, LLC, H1 2015 26
Systemic Sclerosis (Scleroderma) - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 27
Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H1 2015 28
Systemic Sclerosis (Scleroderma) - Pipeline by BioLineRx, Ltd., H1 2015 29
Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H1 2015 30
Systemic Sclerosis (Scleroderma) - Pipeline by Celgene Corporation, H1 2015 31
Systemic Sclerosis (Scleroderma) - Pipeline by Corbus pharmaceuticals, Inc., H1 2015 32
Systemic Sclerosis (Scleroderma) - Pipeline by Daval International Ltd., H1 2015 33
Systemic Sclerosis (Scleroderma) - Pipeline by Digna Biotech, S.L., H1 2015 34
Systemic Sclerosis (Scleroderma) - Pipeline by Dynavax Technologies Corporation, H1 2015 35
Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 36
Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science, Inc., H1 2015 37
Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline plc, H1 2015 38
Systemic Sclerosis (Scleroderma) - Pipeline by iBio, Inc., H1 2015 39
Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva SAS, H1 2015 40
Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune, LLC, H1 2015 41
Systemic Sclerosis (Scleroderma) - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2015 42
Systemic Sclerosis (Scleroderma) - Pipeline by Vida Therapeutics Inc., H1 2015 43
Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana S.L., H1 2015 44
Assessment by Monotherapy Products, H1 2015 45
Number of Products by Stage and Target, H1 2015 47
Number of Products by Stage and Mechanism of Action, H1 2015 49
Number of Products by Stage and Route of Administration, H1 2015 51
Number of Products by Stage and Molecule Type, H1 2015 53
Systemic Sclerosis (Scleroderma) Therapeutics - Recent Pipeline Updates, H1 2015 102
Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2015 129
Systemic Sclerosis (Scleroderma) - Dormant Projects (Contd..1), H1 2015 130
Systemic Sclerosis (Scleroderma) - Discontinued Products, H1 2015 131